Back

VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwNHL 2015 | Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, Canada, discusses the early clinical activity of selinexor, an oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist, for the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and Richter’s transformation.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter